This is a working overview of Preclinical research, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-27 and is reviewed periodically as new material appears.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Bukele's popularity as mayor of San Salvador led some journalists to believe that he would run for president in 2019, but he denied that he would. He eventually expressed interest in running for president with the FMLN, but the party did not consider him as its vice-presidential nominee. He wrote on social media that the FMLN had purged him, and portrayed himself as an independent politician who rejected the country's political system. On 15 October 2017, Bukele announced his intention to run for president in 2019 and form a new political party. He announced the establishment of the Nuevas Ideas party on 25 October 2017 on social media, saying that Nuevas Ideas would seek to remove ARENA and the FMLN from power. During his presidential campaign, Bukele and a network of YouTubers, bloggers, and internet trolls attempted to discredit ARENA and the FMLN. Bukele tried to associate the two parties with the governments of previous presidents that were marred by corruption, using slogans such as "There's enough money when nobody steals" and "Return what was stolen". His campaign promises included the creation of an international commission to combat corruption, the development of a trans-national railroad and a new airport, job opportunities for Salvadorans, and reduced crime.
Following this, a Hezbollah anti-tank missile strike killed an Israeli civilian and wounded five IDF personnel in the kibbutz of Adamit. At night, an Israeli drone strike on a car in Tyre killed two people including Hussein Makki, a Hezbollah field commander. In response to the commander's killing, Hezbollah fired 60 rockets at Mount Meron air traffic control base causing minor damage. They also fired at least one heavy rocket towards the Biranit army base. One IDF soldier was killed and another five were wounded. On 15 May, a rocket launched by the Lebanese branch of Hamas fell short of the intended Israeli target, instead landing on the Lebanese side of the border, killing a Syrian immigrant and wounding four others. A Hezbollah drone crashed in the Lower Galilee for the first time since the start of the conflict. Hezbollah said it launched several drones targeting a surveillance system at an army base near Golani Junction, west of Tiberias. The IDF confirmed that two drones were fired at the Tal Shamayim base, with one being intercepted and the other damaging the Sky Dew aerostat. Later that day, an Israeli airstrike on a car near Tyre killed one Hezbollah member and wounded two other people. The next day, two other Hezbollah members were in another airstrike on another car near in the same area. In retaliation, Hezbollah launched a drone strike on Israeli positions in Metula, wounding three IDF soldiers. On 21 May, an Israeli airstrike near Tyre killed a high-ranking officer in Hezbollah's coastal missile unit.
=== Nuclear weapons decommissioning === Waste from nuclear weapons decommissioning is unlikely to contain much beta or gamma activity other than tritium and americium. It is more likely to contain alpha-emitting actinides such as Pu-239 which is a fissile material used in nuclear bombs, plus some material with much higher specific activities, such as Pu-238 or Po. In the past the neutron trigger for an atomic bomb tended to be beryllium and a high activity alpha emitter such as polonium; an alternative to polonium is Pu-238. For reasons of national security, details of the design of modern nuclear bombs are normally not released to the open literature. Some designs might contain a radioisotope thermoelectric generator using Pu-238 to provide a long-lasting source of electrical power for the electronics in the device. It is likely that the fissile material of an old nuclear bomb, which is due for refitting, will contain decay products of the plutonium isotopes used in it. These are likely to include U-236 from Pu-240 impurities plus some U-235 from decay of the Pu-239; due to the relatively long half-life of these Pu isotopes, these wastes from radioactive decay of bomb core material would be very small, and in any case, far less dangerous (even in terms of simple radioactivity) than the Pu-239 itself.
== History == The safety and effectiveness of donislecel was evaluated in two non-randomized, single-arm studies in which a total of 30 participants with type 1 diabetes and hypoglycemic unawareness received at least one infusion and a maximum of three infusions. Overall, 21 participants did not need to take insulin for a year or more, with eleven participants not needing insulin for one to five years and ten participants not needing insulin for more than five years. Five participants did not achieve any days of insulin independence. The FDA granted marketing approval of Lantidra to CellTrans, Inc.
Sources: en.wikipedia.org
== Background == Ronald Charles Beavis was born in Winnipeg, Manitoba in May 1958. He went to school in Winnipeg and became interested in science at an early age. As a high school student he participated in the Manitoba Science Fair for projects related to chemistry and physics. He received a B.Sc. (Hons) in Zoology and Physics and a Ph.D. (Physics) from the University of Manitoba.
==== Diabetes ==== A meta-analysis reported that vitamin D supplementation significantly reduced the risk of type 2 diabetes for non-obese people with prediabetes. Another meta-analysis reported that vitamin D supplementation significantly improved glycemic control [homeostatic model assessment-insulin resistance (HOMA-IR)], hemoglobin A1C (HbA1C), and fasting blood glucose (FBG) in individuals with type 2 diabetes. In prospective studies, high versus low levels of vitamin D were respectively associated with a significant decrease in risk of type 2 diabetes, combined type 2 diabetes and prediabetes, and prediabetes. A systematic review included one clinical trial that showed vitamin D supplementation together with insulin maintained levels of fasting C-peptide after 12 months better than insulin alone.
=== Latin America === In 2021, Gustavo Gorriti, journalist and founder of corruption-focused IDL-Reporteros news media, wrote a sharply critical editorial in the Washington Post on the impact of 50 years of the war on drugs on Latin America. He described the flow of drugs to the US as an "unstoppable industry" that triggered an economic revolution throughout the region, where the illegal drug trade with its high profit margins far exceeded the potential of legitimate businesses. Corruption among politicians and anti-drug forces soared, even as those in charge were "cultivating close relationships with U.S. enforcement and intelligence agencies." An underclass of poor farmers became economic hostages, depending on drug crops for their survival. The big winners were "the systems built to wage a fight that they soon realized would have no end. ... [The war on drugs] became a source for endless resources, inflated budgets, contracts, purchase orders, power, influence – new economies battling drug trafficking but also dependent on it." At a meeting in Guatemala in 2012, three former presidents from Guatemala, Mexico and Colombia said that the war on drugs had failed and that they would propose a discussion on alternatives, including decriminalization, at the Summit of the Americas in April of that year. Guatemalan President Otto Pérez Molina said that the war on drugs was exacting too high a price on the lives of Central Americans and that it was time to "end the taboo on discussing decriminalization".
Sources: en.wikipedia.org
Itraconazole: Increased plasma level of buspirone Rifampicin: Decreased plasma levels of buspirone Nefazodone: Increased plasma levels of buspirone Haloperidol: Increased plasma levels of buspirone Carbamazepine: Decreased plasma levels of buspirone Grapefruit: Significantly increases the plasma levels of buspirone. See grapefruit–drug interactions. Fluvoxamine: Moderately increased plasma levels of buspirone. Elevated blood pressure has been reported when buspirone has been administered to patients taking monoamine oxidase inhibitors (MAOIs). Buspirone has been found to markedly reduce the hallucinogenic effects of the serotonergic psychedelic psilocybin in humans. This parallels findings in which serotonin 5-HT1A receptor agonists like 8-OH-DPAT attenuate the head-twitch response, a behavioral proxy of psychedelic effects, induced by serotonergic psychedelics in rodents. Paradoxically, however, buspirone enhances the head-twitch response, a behavioral proxy of psychedelic effects, induced by 5-hydroxytryptophan (5-HTP) plus pargyline in rodents.
In two books, Grenzen der Sozialdisziplinierung Austieg und Krise der deutschen Jugendfürsorge von 1878 bis 1932 (The Limits of Social Discipline The Rise and Crisis of German Youth 1878 to 1932) and its sequel, Jugend zwischen Krieg und Krise Lebenswelten von Arbeiterjungen in der Weimarer Republik (Youth Between War and Crisis Lifeworlds of Working Class Boys in the Weimar Republic), Peukert examined how the concept of jugendlicher ("youth") changed from the 19th into the 20th centuries and how the state sought to dominate the lives of youth people via education and mandatory activities. Both books were part of Peukert' habilitation, and reflected his lifelong interest in the experiences of young people in the Imperial, Weimar and Nazi eras.
People with cirrhosis have a 40% lifetime risk of developing hepatic encephalopathy. The median survival after the development of hepatic encephalopathy is 0.9 years. Mild hepatic encephalopathy (also known as covert hepatic encephalopathy), in which symptoms are more subtle, such as impairments in executive function, poor sleep or balance impairment is also associated with a higher risk of hospitalization and death (18% in those with covert hepatic encephalopathy vs 3% in those with cirrhosis and no HE).
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.